Sign In
Buy TNYA
$0.731
+0.0191 (+2.68%)
At Close: Jun 18, 2026
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
05:12pm, Friday, 05'th Jun 2026
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
11:51am, Wednesday, 03'rd Jun 2026
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Sympt
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentia
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
08:00am, Friday, 29'th May 2026
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potential
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
07:40pm, Friday, 15'th May 2026
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
06:25pm, Wednesday, 06'th May 2026
Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.24 per share a year ago.
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th May 2026
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1
SOUTH SAN FRANCISCO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potenti
Financial Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Belite Bio (NASDAQ:BLTE)
02:23am, Tuesday, 31'st Mar 2026
Belite Bio (NASDAQ: BLTE - Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 11'th Mar 2026
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026
Tenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
01:35pm, Thursday, 05'th Mar 2026
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY).
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments
09:10am, Thursday, 05'th Mar 2026
Tenaya Therapeutics said on Thursday it has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases.
